The FDA has extended the emergency use authorisation for Gilead Sciences' antiviral Veklury to include non-hospitalised patients with COVID-19, extending the uses of the drug.
With healthcare systems around the world labouring under the strain of dealing with the Omicron wave of COVID-19 infections, attention is already turning to a new sub-variant that is starti
Poolbeg Pharma has licenced a candidate for nasal immunotherapy, developed by the University of Warwick, targeting respiratory infections, such as influenza and coronavirus.
Preliminary data from an ongoing trial of AstraZeneca's COVID-19 vaccine Vaxzevria has shown that a booster dose stimulates an increase in antibodies against Omicron, as well as other varia
BioNTech and artificial intelligence start-up InstaDeep say they have developed an early warning system that can predict high-risk variants of COVID-19 from their genetic sequences much ear